ePrints

mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition

Lookup NU author(s): Dr Peter Stephens, Professor Ruth Plummer, Professor Nicola CurtinORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Background: Chk1 inhibitors are currently under clinical evaluation as single agents and in combination with cytotoxic chemotherapy. Understanding determinants of sensitivity and novel combinations is critical for further clinical development. Methods: Potentiation of mTOR inhibitor cytotoxicity by the Chk1 inhibitor V158411 was determined in p53 mutant colon cancer cells. DNA damage response, expression levels of repair proteins, cell cycle effects and the contribution of alternative DSB repair pathways were further evaluated by western blotting and high content analysis. Results: mTOR inhibitors AZD8055, RAD-001, rapamycin and BEZ235 induced synergistic cytotoxicity with the Chk1 inhibitor V158411 in p53 mutant colon cancer cells. Reduced FANCD2, RAD51 and RPA70, core proteins in homologous recombination repair (HRR) and interstrand crosslink repair (ICLR), following inhibition of mTOR was associated with increased V158411 induced DSBs and caspase 3-independent cell death. Dual mTOR and Chk1 inhibition activated DNA-PKcs. Cells defective in DNA-PKcs exhibited increased resistance to V158411 with Chk1 expression closely correlated to DNA-PKcs expression in various types of cancer. Conclusions: Down regulation of proteins involved in HRR or ICLR by mTOR inhibitors is associated with increased sensitivity of human tumours to Chk1 inhibitors such as V158411. High levels of DNA-PKcs may be a potential biomarker to stratify patients to Chk1 inhibitor therapy alone or in combination with mTOR inhibitors. (C) 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Publication metadata

Author(s): Massey AJ, Stephens P, Rawlinson R, McGurk L, Plummer R, Curtin NJ

Publication type: Article

Publication status: Published

Journal: Molecular Oncology

Year: 2016

Volume: 10

Issue: 1

Pages: 101-112

Print publication date: 01/01/2016

Online publication date: 25/08/2015

Acceptance date: 17/08/2015

ISSN (print): 1574-7891

ISSN (electronic): 1878-0261

Publisher: Elsevier

URL: http://dx.doi.org/10.1016/j.molonc.2015.08.004

DOI: 10.1016/j.molonc.2015.08.004

Altmetrics

Share